| [1] |
宁光.肥胖与2型糖尿病的流行趋势及其深远影响[J].内科理论与实践ISTIC, 2012, 7(3): 149-51. http://www.cnki.com.cn/Article/CJFDTOTAL-NKLL201203002.htm
|
| [2] |
Xu Y, Wang LM, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-58. doi: 10.1001/jama.2013.168118
|
| [3] |
Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes-realistic estimates for the year 2000[J]. Diabetes Care, 2005, 28(9): 2130-5. doi: 10.2337/diacare.28.9.2130
|
| [4] |
陈玉, 周玲, 徐耀初, 等. 2型糖尿病与遗传和环境因素相互关系的研究[J].中华预防医学杂志, 2002, 36(3): 191-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHYF200203018.htm
|
| [5] |
邓吉容, 唐兰, 李革, 等.肥胖是发生糖尿病的危险因素[J].重庆医学, 2006, 35(10): 886-9. http://www.cnki.com.cn/Article/CJFDTOTAL-CQYX200610008.htm
|
| [6] |
郭立新. 2型糖尿病传统降糖治疗的问题与挑战[J].药品评价, 2014, 11(15): 27-31. http://www.cnki.com.cn/Article/CJFDTOTAL-YPPJ201415007.htm
|
| [7] |
Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-39. doi: 10.1152/physrev.00034.2006
|
| [8] |
Deng WQ, Qiu S, Yang GY, et al. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives[J]. Ther Clin Risk Manag, 2015, 11(3): 1153-62. https://www.ncbi.nlm.nih.gov/pubmed/26309403
|
| [9] |
Kim W1. Egan JM.the role of incretions in glucose homeostasis and diabetes treatment[J]. Pharmacol Rev, 2008, 60(4): 470-512. doi: 10.1124/pr.108.000604
|
| [10] |
Bydureon package insert. Available at http://www.azpicentral.com/bydureon/pi_bydureon.pdfpage=1 [Last accessed:Dec 28th, 2015].
|
| [11] |
Tanzeum package insert.Available at https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF [Last accessed:Dec 28th, 2015].
|
| [12] |
Trulicity package insert. Available at http://pi.lilly.com/us/trulicityuspi.pdf [Last accessed:Dec 28th, 2015].
|
| [13] |
Wysham CH, Macconell LA, Maggs DG, et al. Five-Year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial[J]. Mayo Clinic Proceedings, 2015, 90(3): 356-65. doi: 10.1016/j.mayocp.2015.01.008
|
| [14] |
Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide(HARMONY 2):52 week primary endpoint results from a randomised, placebocontrolled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise[J]. Diabetologia, 2016, 59(2): 266-74. doi: 10.1007/s00125-015-3795-1
|
| [15] |
Umpierrez G, Tofé PS, Pérez MF, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)[J]. Diabetes Care, 2014, 37 (8): 2168-76. doi: 10.2337/dc13-2759
|
| [16] |
Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial[J]. The Lancet Diabetes & Endocrinology, 2014, 2(6): 464-73. http://www.ncbi.nlm.nih.gov/pubmed/24731672
|
| [17] |
Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutideversus insulin glargine in patients with type 2 diabetes on metformin and glimepiride(AWARD-2)[J]. Diabetes Care, 2015, 38(12): 2241-9. doi: 10.2337/dc14-1625
|
| [18] |
Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study[J]. Lancet, 2015, 385 (9982): 2057-66. doi: 10.1016/S0140-6736(15)60936-9
|
| [19] |
Weissman PN, Carr MC, Ye JE, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea[J]. Diabetologia, 2014, 57(12): 2475-84. doi: 10.1007/s00125-014-3360-3
|
| [20] |
Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus Thrice-Daily prandial insulin lispro[J]. Diabetes Care, 2014, 37(8): 2317-25. doi: 10.2337/dc14-0001
|
点击查看大图
下载:
